1266 related articles for article (PubMed ID: 10994545)
1. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
2. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
3. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group.
Cavé H; van der Werff ten Bosch J; Suciu S; Guidal C; Waterkeyn C; Otten J; Bakkus M; Thielemans K; Grandchamp B; Vilmer E
N Engl J Med; 1998 Aug; 339(9):591-8. PubMed ID: 9718378
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.
Sutton R; Venn NC; Tolisano J; Bahar AY; Giles JE; Ashton LJ; Teague L; Rigutto G; Waters K; Marshall GM; Haber M; Norris MD;
Br J Haematol; 2009 Aug; 146(3):292-9. PubMed ID: 19500099
[TBL] [Abstract][Full Text] [Related]
11. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
12. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
[TBL] [Abstract][Full Text] [Related]
13. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
15. Early responses to chemotherapy of normal and malignant hematologic cells are prognostic in children with acute lymphoblastic leukemia.
Laughton SJ; Ashton LJ; Kwan E; Norris MD; Haber M; Marshall GM
J Clin Oncol; 2005 Apr; 23(10):2264-71. PubMed ID: 15800317
[TBL] [Abstract][Full Text] [Related]
16. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
[TBL] [Abstract][Full Text] [Related]
17. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
19. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]